Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Keywords: indacaterol COPD Long-acting beta2-agonist (LABA)
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 90
Healthy volunteers: no

Brief summary:
In this 12-week study, patients were randomized to either open-label indacaterol or standard of care for Chronic Obstructive Pulmonary Disease (COPD) treatment; efficacy and safety were assessed.

Detailed description:

Arms:
arm 1: Indacaterol 150 µg once-daily via single-dose dry powder inhaler arm 2: Participants' current long-acting beta2-agonist (LABA) bronchodilator therapy

Interventions: intervention 1: Indacaterol intervention 2: Long-acting beta2-agonist
Intervention descriptions: intervention 1: Indacaterol 150 µg once-daily via single-dose dry powder inhaler intervention 2: Long-acting beta2-agonist (LABA) bronchodilator monotherapy via inhaler twice daily

Protocol document: